INmune Bio Q4 EPS $(0.47) Misses $(0.44) Estimate, Sales $28.00K Miss $40.00K Estimate
Portfolio Pulse from dijoy@benzinga.com
INmune Bio (NASDAQ:INMB) reported Q4 earnings with a per-share loss of $(0.47), missing the $(0.44) estimate, and sales of $28.00K, missing the $40.00K estimate. This represents a significant decrease from the previous year's performance.
March 28, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
INmune Bio reported a larger-than-expected Q4 loss and a significant sales miss, indicating a substantial year-over-year decline.
The reported earnings miss and sales shortfall, especially when compared to the previous year's figures, suggest potential operational or market challenges. This could lead to negative investor sentiment in the short term, impacting the stock price negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100